Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 5, 2005

View Archived Issues

Several voltage-gated calcium channel subunits pinpointed in pain

SIRS-Lab and BioSite collaborate on sepsis markers

Update on phenoxodiol development

MultiCell receives SBIR grant for protein development for sepsis treatment

CCK antagonism improves opioid sensitivity for the treatment of SCI pain

Add-on quetiapine improves pain, depression and anxiety in fibromyalgia patients

Galiximab demonstrates favorable safety profile in follicular lymphoma patients

FDA decision on Neurodex NDA expected in October

Phase II lung cancer study of AS-1404 reaches enrollment target

Novartis bids to acquire remaining Chiron shares

Structural GenomiX changes name to SGX Pharmaceuticals

Antisense Therapeutics to resume phase IIa study of ATL-1102

DOV and Merck & Co. amend license agreement

Zealand Pharma completes second stage of international financing

Cephalon and McNeil to copromote Attenace

Altachem cleared for phase I study of ACP-SL017 for actinic keratosis

Series B financing at Biolex Therapeutics supports pipeline development

Therapeutic agents for gastrointestinal disorders claimed in patent literature

Clinical data confirm Exubera improves glycemic control of patients with type 2 diabetes

New therapeutics for cancer disclosed in recent patents

Orally active antiestrogen with antitumor properties developed by Chugai

Novel orally bioavailable TACE inhibitor displays efficacy in preclinical model of inflammation

Novel AR antagonist BMS-591305 expected to advance to clinical testing

Paroxetine increases suicidal activity in adults

Clazosentan shows promise in the prevention of cerebral vasospasm after SAH

DB-289 induces parasite clearance in Plasmodium-infected patients